ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
60,989.35
0.32%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) News

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KPTI
DateTimeSourceHeadlineSymbolCompany
08/05/202421:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202421:05PR Newswire (US)Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202412:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202412:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202412:30PR Newswire (US)Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202412:30PR Newswire (US)Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029NASDAQ:KPTIKaryopharm Therapeutics Inc
07/05/202421:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
02/05/202421:30PR Newswire (US)Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
01/05/202421:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
24/04/202421:01PR Newswire (US)Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:KPTIKaryopharm Therapeutics Inc
01/04/202421:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
06/03/202421:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/03/202421:05PR Newswire (US)Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202400:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202400:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202400:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202400:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202400:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
05/03/202400:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
01/03/202421:05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202422:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202422:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202422:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202422:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202422:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202422:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202412:43Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202412:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202412:30PR Newswire (US)Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
22/02/202412:00PR Newswire (US)Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KPTI

Your Recent History

EU
D343T
D343T
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved